Invesco Biotechnology & Genome ETF
PBE
94 hedge funds and large institutions have $82M invested in Invesco Biotechnology & Genome ETF in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 36 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0.21% more ownership
Funds ownership: 36.45% → 36.66% (+0.21%)
0% more funds holding
Funds holding: 94 → 94 (0)
2% less capital invested
Capital invested by funds: $83.9M → $82M (-$1.89M)
58% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mariner
Overland Park,
Kansas
|
+$757K |
| 2 |
GKWIM
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
|
+$633K |
| 3 |
Goldman Sachs
New York
|
+$343K |
| 4 |
RA
RFG Advisory
Birmingham,
Alabama
|
+$290K |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$878K |
| 2 |
OCM
One Capital Management
Westlake Village,
California
|
-$683K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$464K |
| 4 |
JP Morgan Chase
New York
|
-$451K |
| 5 |
JIC
Joel Isaacson & Co
New York
|
-$427K |
PBE Hedge Fund Activity: Q2 2025 in Review
94 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2025, worth a combined $82M — down 2.2% from $83.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PBE positions and 5 closed out — a net gain of 1 holder — while 15 added to existing stakes and 36 trimmed.
The largest buyer was Mariner, opening a new position worth an estimated $757K. The largest seller was Creative Planning, cutting an estimated $878K.
- 94 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $82M of Invesco Biotechnology & Genome ETF stock for Q2 2025, down 2.2% quarter-over-quarter.
- 6 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2025 and 5 closed out, a net change of +1 holder.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2025 was Mariner, an estimated $757K added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2025 was Creative Planning, an estimated $878K sold.
Based on aggregated 13F filings for Q2 2025.